Xeljanz Stroke Lawsuit Filed Against Pfizer for Gross Negligence in Failing to Warn About Drug Risks
A Xeljanz stroke lawsuit claims Pfizer failed to adequately warn about the drug's heart risks.
Tag Archives: Rheumatoid Arthritis
-
-
Rheumatoid Arthritis Risk Linked to Air Pollution Exposure
A new study links air pollution exposure to an increased risk of autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease.
-
Acthar Settlement Results in $260M Payment to Resolve DOJ Fraud and Illegal Kickback Allegations
Mallinckrodt will pay $260 million to resolve illegal Medicaid fraud and kickback claims brought against it by whistleblowers and the federal government over its marketing of Acthar gel.
-
Xeljanz Lawsuit Filed Over Failure to Warn About Risk of Blood Clots, Pulmonary Embolisms
A Xeljanz lawsuit claims Pfizer misled the public about the safety of the rheumatoid arthritis drug, leading to a man suffering a life-threatening blood clot.
-
Makers of Oluminant Withdraw Lupus Treatment Approval Request in Face of JAK-Inhibitor Health Risks
A request for approval for Olumiant to treat lupus has been withdrawn, and the manufacturers expect the FDA to reject an atopic dermatitis approval request in the face of growing…
-
Rinvoq Approved As Atopic Dermatitis Treatment Despite Heart, Cancer Risks
The FDA has approved Rinvoq for the treatment of atopic dermatitis despite cancer and heart problem fears.
-
Despite Side Effects of Xeljanz and Rinvoq, FDA Still Approves New Indications After Updated Warnings
The FDA has granted new approvals for rheumatoid arthritis drugs Xeljanz and Rinvoq despite concerns over heart, cancer and blood clot side effects.
-
FDA Worried Jakafi May Have Cancer, Heart Risks Similar to Xeljanz
The FDA has delayed an expanded approval for the drug Jakafi, potentially due to concerns over heart and cancer risks linked to Pfizer's Xeljanz, a similar drug.
-
Speculation Mounts for Potential FDA Panel Review of Health Risks from Xeljanz, Other JAK Inhibitors
Some believe the FDA is preparing to review the risks and benefits of Xeljanz and similar drugs given recent cancer and heart concerns.
-
Investigation of Xeljanz Cancer and Heart Risks Launched in Canada
Growing concerns have led to Health Canada announcing a Xeljanz safety review, to determine whether more warnings or actions are needed following studies suggesting the ulcerative colitis drug could increase…